Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APG-1842
- Development stage
- Discontinued
- Lead developer
- Ascentage Pharma
- Modality
- Small Molecules
01
Overview
APG-1842 is a small molecule, covalent inhibitor specifically targeting the KRAS G12C mutant protein. It acts by irreversibly binding to the inactive (GDP-bound) form of KRAS G12C, thereby blocking downstream signaling pathways that drive tumor growth in cancers harboring this mutation. Developed by Ascentage Pharma, APG-1842 was investigated for its potential in treating solid tumors with KRAS G12C mutations, including non-small cell lung cancer (NSCLC), colorectal cancer, and gastric cancer. The drug demonstrated high selectivity and potency in preclinical studies but has not advanced beyond preclinical development[1][3][7][9].
02
Targets
KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)
Beyond the preview
Go deeper on APG-1842.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APG-1842.